Janus Henderson Group
SKYE icon

Janus Henderson Group’s Skye Bioscience SKYE Stock Holding History

Janus Henderson Group’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-113,206
Closed -$7.29M – 2560
2024
Q2 		$7.29M Buy
+113,206
New +$10.7M ﹤0.01% 730

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Janus Henderson Group's SKYE Position: Q3 2024 in Review

Janus Henderson Group sold out of Skye Bioscience (SKYE) in Q3 2024, closing a stake of 113,206 shares — an estimated $7.29M sold.

Janus Henderson Group first reported a position in SKYE in Q2 2024 and held it in 1 quarter. The position peaked at $7.29M in Q2 2024. 66 funds tracked by Wall St. Rank hold SKYE as of Q3 2024.

  • Janus Henderson Group reported no remaining Skye Bioscience position as of Q3 2024 after selling out during the quarter.
  • Janus Henderson Group sold 113,206 Skye Bioscience shares in Q3 2024, an estimated $7.29M.
  • Janus Henderson Group first reported a position in Skye Bioscience in Q2 2024 and held it in 1 quarter.
  • Janus Henderson Group's Skye Bioscience position peaked at $7.29M in Q2 2024.
  • 66 funds tracked by Wall St. Rank held Skye Bioscience as of Q3 2024.

Based on Janus Henderson Group's 13F filing for Q3 2024, filed 14 Nov 2024.